Wordt geladen...
Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
Sorafenib and lenvatinib are the only multikinase inhibitors (MKIs) approved for the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC). Although they have been demonstrated to improve progression free survival and overall response rate, the risk of toxicities is very...
Bewaard in:
| Gepubliceerd in: | J Pers Med |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8306329/ https://ncbi.nlm.nih.gov/pubmed/34357141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11070674 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|